ZetaGen Therapeutics commercializes a small molecule-based osteoinductive platform.
ZetaGen Therapeutics has raised $12.9M in total funding. The most recent round was Series B. The last funding was announced in January 2025.
ZetaGen Therapeutics's investors include National Cancer Institute, New York Ventures, JStar Capital Investments, MedTech Innovator, Consolidated Investment Group.
ZetaGen Therapeutics is headquartered in Syracuse, United States.
ZetaGen Therapeutics commercializes a small molecule-based osteoinductive platform.
ZetaGen Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ZetaGen Therapeutics — Funding & Investors." VCBacked, January 23, 2025, https://www.vcbacked.co/company/zetagen-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). ZetaGen Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/zetagen-therapeutics
{{cite web |title=ZetaGen Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/zetagen-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated